Infliximab is indicated for the treatment of inflammatory conditions in Rheumatology, Gastroenterology, and Dermatology2.
Approved in more than 80 countries worldwide24.
Please refer to the useful resources section to read more about the studies.
†Remicade® is a registered trademark of MSD.
ΩCumulative exposure from August 1998 through August 2016. Uses include rheumatoid arthritis, Crohn’s disease, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and ulcerative colitis.
*CT-P13 is marketed under different brand names including INFLECTRA® and REMSIMA®.
CD, Crohn’s disease; TNFi, Tumour necrosis factor inhibitor; US, United States; EU, European Union; ECCO, European Crohn's and Colitis Organisation; NICE, The National Institute for Health and Care Excellence; BSG, British Society of Gastroenterology; BSR, British Society of Rheumatology; DB, Double blind; RCTs, Randomised controlled trials; RA, Rheumatoid arthritis; AS, Ankylosing spondylitis; IBD, Inflammatory bowel disease; UC, Ulcerative colitis; TDM, Therapeutic drug monitoring.
PP-IFA-GBR-0322. December 2018